Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD, Food Effect, and DDI Study of Risdiplam in Healthy Men
NCT02633709Phase 1Completed
- Sponsor
- Roche
- Start
- Jan 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of risdiplam in spinal muscular atrophy (SMA) (5 arms), sponsored by Roche. Primary endpoints: Percentage of Participants with Adverse Events up to 28 days, Percentage of Participants with Laboratory Test Abnormalities up to 28 days and 2 more. Started Jan 2016; status: completed.
02
Drugs
risdiplam
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT02633709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02633709.